El interés en corto de Johnson & Johnson da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Johnson & Johnson. Los datos de interés en corto se actualizan cada dos semanas.

Johnson & Johnson (NYSE:JNJ) Bolsa, Informe de interés en corto

JOHNSON & JOHNSON

Johnson & Johnson

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.

Earnings

News

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

Johnson &amp; Johnson reportará ganancias del cuarto trimestre. Analiza sus ingresos, expansión de Spravato y opiniones de analistas clave.

Johnson &amp; Johnson (JNJ) reportará ganancias del 4T: ¿Qué opinan los analistas?

IBKR

NFLX

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este miércoles: ABT, NFLX, PG, IBKR y JNJ.

5 acciones en el foco este miércoles: ABT, NFLX, PG, IBKR y JNJ

Dividends

AMGN

AMZN

CSCO

SPDR Dow Jones Industrial Average ETF Trust

NVDA

Descubre las acciones del Dow Jones con los rendimientos por dividendos más altos para 2025. Conoce estrategias populares.

Acciones con mayores dividendos del Dow Jones: Las mejores opciones para 2025

With U.S. President Donald Trump&#8217;s <a target="_blank" href="https://www.benzinga.com/topic/tariffs" rel="noreferrer noopener">tariffs</a>, HC Wainwright analyst writes that investors are looking for companies with macroeconomic moats that protect against tariff exposure and regulatory uncertainty.
Legend Biotech Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEGN#NASDAQ">LEGN</a>) has no material exposure to tariffs, the analyst stated.
The cell therapy company&#8217;s lead product, Carvykti, is a one-time treatment for relapsed or refractory&nbsp;multiple myeloma, which it develops and markets with collaborator Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>).
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/41093953/johnson-johnson-legend-biotech-partnered-blood-cancer-drug-extends-overall-survival" rel="noreferrer noopener">Johnson &amp; Johnson/ Legend Biotech Partnered Blood Cancer Drug Extends Overall Survival, Support Use In Previously Treated Patients</a>
Analyst Mitchell Kapoor notes that Legend manufactures in the U.S. for 100% of the commercial Carvykti patients in the U.S. and Europe.
In the first quarter of 2025, the company initiated commercial production of Carvykti&nbsp;at a Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) production facility under the master manufacturing and supply agreement among <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44242720/legend-biotech-reports-fourth-quarter-and-full-year-2024-results-and-recent-highlights" rel="noreferrer noopener">Legend, Janssen, and Novartis</a>.
Analyst Kapoor adds that Legend does not have to import materials for CAR-T manufacturing and thus has no material exposure to tariffs or transfer pricing.
&#8220;Legend has no tariff exposure, creating an attractive opportunity to own shares in unpredictable macroeconomic times,&#8221; HC Wainwright highlights. The analyst reiterates the Buy rating, with a <a target="_blank" href="https://www.benzinga.com/quote/LEGN/analyst-ratings" rel="noreferrer noopener">price target of $75</a>.
While Legend Biotech has several drugs in development, analyst Kapoor writes the biggest factor driving its stock is how well Carvykti performs as an earlier treatment for multiple myeloma.
The analyst is confident that Carvykti will be widely adopted in earlier lines of treatment, as the data show it&#8217;s among the best available options. &#8220;Thus, we see LEGN as considerably insulated from the regulatory risks plaguing the biotech space, and we view this as a compelling time to own the stock,&#8221; says HC Wainwright analyst.
Carvykti remains very favorably positioned compared to competitors, citing robust efficacy (particularly durability) data in the fourth- and second-line treatments, leaving little room for improvement.
HC Wainwright writes that the drug is far ahead of competitors, as it is already approved for second-line Relapsed/refractory multiple myeloma (RRMM). New therapies usually start by getting approved for use in patients who have already tried other treatments. Over time, they can receive additional approvals to be used earlier in the treatment process.
Price Action: LEGN stock is up 1.86% at $30.81 at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/contracts/25/04/44695936/nokia-inks-5-year-deal-with-fibrus-to-strengthen-network-security-and-analytics" target="_blank" rel="noreferrer noopener">Nokia Inks 5-Year Deal with Fibrus To Strengthen Network Security And Analytics</a></li>
</ul>

Analyst Color

Biotech

Health Care

General

LEGN

Cell Therapy Maker Legend Biotech Is An 'Attractive Opportunity' Due To No Material Tariff Exposure: Analyst

Wall Street&#8217;s worst sell-off since the 2020 pandemic has sent several major indices into correction or bear territory, prompting <a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44697600/stocks-rebound-chipmakers-soar-on-trade-deal-hopes-bitcoin-lags-whats-driving-markets-tuesday">a flight to safety</a>. 
<a href="https://www.benzinga.com/etfs">ETFs that provide exposure </a>to consumer staples, utilities, and healthcare—sectors that have historically been considered defensive during downturns—are now in the limelight.
Some of the top choices are:
<ul>
<li>SPDR Select Sector Fund &#8211; Consumer Staples (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>): This exchange-traded fund follows businesses that make common items such as food, drinks, and household goods. Sales of these necessities would generally continue regardless of economic downturns. Procter &amp; Gamble Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>), Costco Wholesale Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) and Walmart, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) are among its holdings.</li>
</ul>
<ul>
<li>SPDR Select Sector Fund — Utilities (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>): Utility firms offer essential services such as electricity and water, so they would be favorites among income-hungry investors amid times of greater uncertainty. The portfolio includes NextEra Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEE#NYSE">NEE</a>) and Pg&amp;E Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCG#NYSE">PCG</a>).</li>
</ul>
<ul>
<li>Vanguard Health Care ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VHT#NYSE">VHT</a>): Healthcare spending generally holds up in tough times, and VHT provides exposure to a blend of drugstore chains, medical device manufacturers, and healthcare providers. Eli Lilly &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) and Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) are among the top holdings.</li>
</ul>
Also Read: <a href="https://www.benzinga.com/25/04/44695765/crypto-etfs-sink-as-trump-tariffs-trigger-panic-this-could-reset-the-macro-narrative">Trump Tariffs Spark $800M Crypto ETF Rout: Can The Macro Narrative Shift?</a>
Dividend-oriented ETFs are also attracting attention. The iShares Core High Dividend ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HDV#NYSE">HDV</a>), which owns a portfolio of financially healthy U.S. firms that pay high dividend yields, protects against declining stock prices with consistent income.
Value investing is also gaining traction. The Vanguard Value ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTV#NYSE">VTV</a>), which tracks large-cap stocks that are undervalued relative to their fundamentals, is considered a less risky means of remaining invested while reducing exposure to growth stocks with volatile price swings.
The move into defensive positioning occurs as investors process the latest ratcheting up of U.S.-China trade tensions. According to the White House, the U.S. tariff rate on Chinese imports will spike to 104% at 12:01 a.m. ET on Wednesday unless China removes retaliatory tariffs against the U.S.
The risk of blanket tariffs — a 10% base tariff on all imports to the U.S. and higher rates on major trading partners such as the EU, India, Taiwan, and Vietnam — has unsettled markets. Uncertainty about a supposedly planned 90-day tariff break, which the White House <a href="https://www.benzinga.com/news/25/04/44671308/stock-market-surge-evaporates-as-headline-roulette-plagues-traders-fake-news-white-house-says-in-response-to">called &#8220;fake news</a>,&#8221; contributed to the fluctuations.
<a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44645681/jpmorgan-raises-recession-risk-to-60-as-largest-us-tax-hike-in-60-years-hits-global-economy?_gl=1&#x2A;1mnei8t&#x2A;_gcl_au&#x2A;NzQyMjgxNjUuMTczNzYwNzI4NQ..&#x2A;_ga&#x2A;ZGVsZXRlZA..&#x2A;_ga_V7ZK73W7N0&#x2A;MTc0NDAyMzE1Ny4yNDYuMS4xNzQ0MDIzMjMyLjAuMC4w">JPMorgan now sees</a> a U.S. recession in the second half of 2025 at 60%, and Goldman Sachs has <a href="https://www.benzinga.com/25/04/44662991/goldman-sachs-raises-risk-of-recession-to-45-jefferies-calls-tariffs-a-free-hall-pass-for-tech-giants-to-reset-their-goals">increased the chances</a> of a recession in the next 12 months to 45%.
In that environment, strategists say it&#8217;s not about going after gains — it&#8217;s about limiting losses.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/etfs/new-etfs/25/04/44698247/bitwise-turns-crypto-volatility-into-yield-with-new-etf-trio">Bitwise Turns Crypto Volatility Into Yield With New ETF Trio</a></li>
</ul>
Image: Shutterstock

Asia

Broad U.S. Equity ETFs

ETFs

COST

As Trump Tariffs Spark Panic, Investors Rush Into These 5 'Recession-Proof' ETFs

Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) on Tuesday announced results from additional analyses of the Phase 3 Vivacity-MG3 study and the ongoing open-label extension&nbsp;(OLE), evaluating the long-term efficacy and safety of nipocalimab in a broad population of antibody-positive adults with <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">generalized myasthenia gravis (gMG)</a>.
Patients treated with nipocalimab plus standard of care (SOC) maintained improvements in their MG-ADL (activities of daily living)&nbsp;and QMG (quantifies disease severity)&nbsp;scores over 84 weeks with sustained reductions <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n44678645/johnson-johnson-highlights-new-data-that-showcase-the-strength-of-nipocalimab-demonstrating-long-t" rel="noreferrer noopener">in total immunoglobulin G (IgG)</a>.
Nipocalimab demonstrated a mean change in MG-ADL of -5.64 (p&lt;0.001) after 60 weeks in the OLE for study participants receiving nipocalimab and SOC, and -6.01 (p&lt;0.001) mean change&nbsp;for study participants who transitioned from placebo and SOC to nipocalimab and SOC.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44651117/johnson-johnsons-tremfya-shows-efficacy-across-multiple-domains-in-late-stage-psoriatic-arthritis-study" rel="noreferrer noopener">Johnson &amp; Johnson&#8217;s Tremfya Shows Efficacy In Late-Stage Psoriatic Arthritis Study</a>
In the antibody-positive population, 45%&nbsp;of patients receiving steroids at the OLE baseline were able to decrease or discontinue steroids at the time of this data cut by more than half of the baseline dose.
<ul>
<li>Among these patients, the mean dose of prednisone decreased from 23 to 10&nbsp;mg daily.</li>
</ul>
Nipocalimab had a consistent and tolerable safety profile throughout the OLE phase.
Additional findings from the Phase 3 Vivacity-MG3 study indicate that patients treated with nipocalimab plus SOC achieved statistically significant improvements in their QMG score by -4.9 versus placebo plus SOC (p&lt;0.001) over weeks 22 and 24.
Patients in the nipocalimab plus SOC treatment group were four times more likely to sustain symptom improvement at 20 weeks than the placebo plus SOC group, as measured by a three- or greater-point improvement on the QMG score.
Results show significantly more patients treated with nipocalimab (36.4%) versus placebo (10.5%, p&lt;0.001) spent greater than 75% of the study duration, demonstrating improvements in the QMG score.
A reduction of more than three points in the QMG score indicates a decrease in the severity of the patient&#8217;s symptoms due to improvements in muscle strength, allowing patients to carry out important daily activities such as swallowing and chewing.
Price Action: JNJ stock is down 0.21% at $150.31 at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/04/44695622/amazon-touts-ai-milestone-says-new-model-outshines-gpt-4o-in-real-time-speech" target="_blank" rel="noreferrer noopener">Amazon Touts AI Milestone, Says New Model Outshines GPT-4o In Real-Time Speech</a></li>
</ul>
Image via Shutterstock

Large Cap

Johnson & Johnson's New 'Compelling Data' Shows Sustained Symptom Improvement In Muscular Disease Patients

<ul>
<li>New compelling results demonstrate 18 months of both sustained reduction in immunoglobulin G antibodies and sustained improvement in gMG symptoms in pivotal Vivacity-MG3 study and open-label extension phase</li>
<li>Up to 128 weeks and 180 patient years of follow-up in the open-label extensiona confirm a safety profile consistent with the Phase 3 Vivacity-MG3 study&nbsp;</li>
<li>45% of the patients receiving steroids at open-label extension baseline were able to decrease or discontinue their steroid use&nbsp;</li>
<li>Additionally, the nipocalimab plus standard of care (SOC) group demonstrated four times greater odds of improving and maintaining the strength and function of different muscle groups as measured by QMGb&nbsp;response versus placebo plus SOC in the 24-week double blind phase of the study&nbsp;</li>
</ul>

Johnson & Johnson Presents New Data Showing Long-Term Sustained Disease Control With Investigational Nipocalimab In Adults With gMG

Shares of the Health Care Select Sector SPDR Fund (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NASDAQ">XLV</a>) are trading lower by 8.6% to $132.86 over the past week as tariff announcements from President Donald Trump last week spooked investors and <a href="https://www.benzinga.com/government/regulations/25/04/44670193/wall-street-turmoil-deepens-as-trump-threatens-massive-china-tariffs-bitcoin-wobbles-at-78k-whats-driving-markets-monday">dragged major sectors</a> of the market lower. 
While healthcare is often viewed as a defensive play during times of uncertainty, the <a href="https://www.benzinga.com/general/health-care">sector</a> is not immune to the broader economic implications of escalating trade tensions.
<h2 class="wp-block-heading">What Is XLV?</h2>
The Health Care Select Sector SPDR Fund is an exchange-traded fund that tracks the performance of the Health Care Select Sector Index, which includes large U.S. healthcare companies across pharmaceuticals, biotechnology, healthcare equipment and managed care. Top holdings include Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), UnitedHealth Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) and Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) .
Although healthcare demand tends to be less cyclical than sectors like industrials or energy, many of XLV's components are <a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44667104/speculators-raise-wagers-on-fed-emergency-rate-cuts-as-theories-of-self-induced-crash-gather-pace">exposed to global markets</a>, supply chains and regulatory dynamics—all of which can be disrupted by a trade war.
Read Also: <a href="https://www.benzinga.com/news/25/04/44670684/whats-going-on-with-financial-select-sector-spdr-fund-xlf">What&#8217;s Going On With Financial Select Sector SPDR Fund (XLF)?</a>
<h2 class="wp-block-heading">Why Are Tariffs Hitting Healthcare—and XLV?</h2>
At first glance, healthcare might seem like an unlikely victim of tariff tensions, but the industry is more globally interconnected than it appears. Here's how tariff escalation is weighing on XLV and its underlying holdings:
<ul>
<li>Global Supply Chain Disruptions: Many medical devices and pharmaceutical ingredients are manufactured or sourced overseas. Tariffs on imported materials from countries like China can increase production costs for companies like Medtronic and Abbott Laboratories, which rely on <a href="https://www.benzinga.com/25/04/44663112/us-families-to-see-3800-annual-price-hike-says-experts-even-as-trump-indicates-tariff-windfall-of-tens-of-billions-of-dollars">international supply chains</a> to maintain margins and deliver products at scale. </li>
<li>Pricing Pressures Intensify: Healthcare companies already face intense political scrutiny over pricing. Tariffs add another <a href="https://www.benzinga.com/news/global/25/04/44668830/we-want-fairness-white-house-trade-adviser-navarro-says-trump-administration-is-focused-on-non-tariff-cheating">layer of cost inflation</a> that may be difficult to pass along to consumers or insurers. That's especially challenging for drugmakers and device manufacturers that operate under tight pricing regulations or depend on long-term contracts. </li>
<li>Global Growth Matters: Multinational pharmaceutical companies such as Pfizer and Johnson &amp; Johnson derive a significant share of their revenue from international markets. A slowdown in global economic growth due to <a href="https://www.benzinga.com/25/04/44661965/trumps-reciprocal-tariff-threat-wipes-out-nearly-18-trillion-from-magnificent-7-dan-ives-warns-it-could-set-us-tech-back-a-decade-investors-know-math-and-the-sad-reality">trade tensions</a> can dampen demand for branded drugs and medical products abroad, squeezing top-line growth. </li>
<li>Market Volatility Hits Sentiment: Even though healthcare is traditionally considered defensive, the sector is still susceptible to broader market moves. Investors often rotate out of equities—including healthcare—during times of heightened uncertainty. Additionally, biotech and life sciences stocks, many of which are included in XLV, tend to be more volatile and sensitive to shifts in investor risk appetite.</li>
</ul>
Read Also: <a href="https://www.benzinga.com/government/regulations/25/04/44670193/wall-street-turmoil-deepens-as-trump-threatens-massive-china-tariffs-bitcoin-wobbles-at-78k-whats-driving-markets-monday">Wall Street Turmoil Deepens As Trump Threatens Massive China Tariffs, Bitcoin Wobbles At $78K: What&#8217;s Driving Markets Monday?</a>

Why Health Care Select Sector SPDR Fund (XLV) Is Moving

Halozyme Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) (Halozyme) today announced that Janssen-Cilag International NV, a Johnson &amp; Johnson company, has received European Commission (EC) marketing authorization of&nbsp;the subcutaneous (SC) formulation of RYBREVANT&#xAE; (amivantamab), in combination with&nbsp;LAZCLUZE&#xAE; (lazertinib), for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon&nbsp;19 deletions or exon 21 L858R substitution mutations. Additionally, it is approved as a&nbsp;monotherapy for adult patients with advanced NSCLC with activating EGFR exon 20 insertion mutations after the failure of platinum-based therapy.
Subcutaneous amivantamab is co-formulated Halozyme's ENHANZE&#xAE; drug delivery technology.

HALO

Halozyme Therapeutics Announced That Janssen-Cilag International NV, A J&J Company, Has Received European Commission Marketing Authorization Of The Subcutaneous Formulation Of RYBREVANT, In Combination With LAZCLUZE, For The First-Line Treatment Of Adult Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 19 Deletions Or Exon 21 L858R Substitution Mutations

<a href="https://www.jnj.com/media-center/press-releases/european-commission-approves-johnson-johnsons-subcutaneous-darzalex-daratumumab-based-quadruplet-regimen-for-the-treatment-of-patients-with-newly-diagnosed-multiple-myeloma-regardless-of-transplant-eligibility" title="https://www.jnj.com/media-center/press-releases/european-commission-approves-johnson-johnsons-subcutaneous-darzalex-daratumumab-based-quadruplet-regimen-for-the-treatment-of-patients-with-newly-diagnosed-multiple-myeloma-regardless-of-transplant-eligibility">https://www.jnj.com/media-center/press-releases/european-commission-approves-johnson-johnsons-subcutaneous-darzalex-daratumumab-based-quadruplet-regimen-for-the-treatment-of-patients-with-newly-diagnosed-multiple-myeloma-regardless-of-transplant-eligibility</a>

Johnson & Johnson Announces The European Commission Has Approved Its Subcutaneous Darzalex-Based Quadruplet Regimen For The Treatment Of Patients With Newly Diagnosed Multiple Myeloma, Regardless Of Transplant Eligibility

The new trade war precipitated by President <a href="https://www.benzinga.com/25/04/44647999/trumps-tariff-war-could-take-us-tech-industry-back-a-decade-while-china-steam-rolls-ahead-analyst-says">Donald Trump‘s tariffs</a> has turned investors against companies heavily involved in the import-export market. Instead, companies with stable revenue, low valuations and little exposure to trade are rising.
Especially ones that offer nice dividends. Today, let&#8217;s look at a couple of examples.
Then, we will consider the three best dividend funds to capture this trend.
Consider companies like Verizon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>) (6.07% dividend right now), which does not purchase or sell products in overseas markets, or tobacco giant Altria (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MO#NYSE">MO</a>) (7.25% dividend), which sells most of its products in the USA.
Past that, dividend stocks and funds have been performing well in 2025.
&#8220;Dividend-oriented strategies have performed well in the first quarter of 2025,&#8221; said William Connor, CFA, CFP, partner at Sax Wealth Advisors. &#8220;The SPDR S&amp;P Dividend ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SDY#NYSE">SDY</a>) generated a positive return during Q1 2025 of 2.71%, which compares favorably with the S&amp;P 500, which lost 4.55% in the first quarter of 2025.&#8221;
Although the S&amp;P 500 has outperformed over the last year, increasing 7.1% while the SDY was up 3.86%, dividend stocks tend to be less volatile, often due to the more defensive nature of the economic sectors in which they operate. &#8220;Ned Davis Research conducted a study of dividend-paying companies compared to non-dividend-paying companies,&#8221; Connor noted. &#8220;The results illustrated what many investors intuitively feel; dividend stocks exhibit lower volatility than non-dividend payers and a broad index like the S&amp;P 500.&#8221;
That data matters at a time when the Trump administration has sought a level playing field on tariffs, causing major upheaval in global markets.
&#8220;The impact of potential tariffs on the economy is unknowable at this point, given that the specifics have yet to be announced,&#8221; Connor said. &#8220;What is likely is the uncertainty around tariffs (amounts, sectors, and exemptions, for example) is leading many investors to be concerned about the outlook for US stocks.&#8221;
Since dividend stocks have been less volatile over time than the average stock, it&#8217;s reasonable for investors concerned with the growth outlook to focus on them. &#8220;The dividend payment provides a steady, predictable return to help manage volatility and risk,&#8221; Connor added.
Given the volatility linked to trade and tariffs, will that be the case going forward? Yes and no.
&#8220;In the short-term, tariffs are likely to be seen as a negative for dividend stocks – particularly globally-focused companies – as tariffs increase the price of imported goods or raw materials, which can impact profitability,&#8221; said Rob Edwards, managing director and senior portfolio manager at Florida-based Edwards Asset Management.
In the long run, however, Edwards believes dividend stocks should prosper, even with tariffs, as they are typically more mature companies that have proven resilient to many economic challenges.
&#8220;I believe that you should own dividend stocks to invest throughout an entire market cycle, not around it,&#8221; he noted.
<h2 class="wp-block-heading">Three Solid Dividend ETFs</h2>
Rather than take your chances with one or two individual dividend-paying stocks, curb some downside risk by leveraging dividend exchange-traded funds, where you can also get some bang for your buck.
<h3 class="wp-block-heading">SPDR S&amp;P Dividend ETF</h3>
Like the best dividend ETFs, the SPDR S&amp;P Dividend ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SDY#NYSE">SDY</a>) is a tax-efficient, low-cost, highly liquid investment with broad exposure to high-quality stocks.
The fund aims to produce investment results corresponding to the total return performance of the S&amp;P High Yield Dividend Aristocrats Index. &#8220;The fund really focuses on S&amp;P Composite 1500 Index companies that have followed a managed-dividends policy of consistently increasing dividends every year for at least 20 consecutive years,&#8221; Connor said.
Dividend payments are about 0.80% and the fund has returned 4.76% year-to-date.
Dividend ETFs are not flashy, but they&#8217;re steady, and that&#8217;s what Steven Kibbel, a financial planner and chief editorial advisor at Gold IRA Companies in Franklin, Tenn. &#8220;Many people, especially retirees I work with, like them because they give regular income without needing to sell shares. That matters when you&#8217;re trying to make your savings last. These funds mostly hold big companies that keep paying dividends no matter what&#8217;s going on in the market. Think utilities, healthcare, and food companies. That kind of thing.&#8221;
<h3 class="wp-block-heading">Schwab U.S. Dividend Equity ETF</h3>
One dividend fund Kibbel favors holds those same traits &#8211; Schwab U.S. Dividend Equity ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHD#NYSE">SCHD</a>).
&#8220;It&#8217;s simple, low-cost, and holds strong companies with solid financials,&#8221; he said. &#8220;I&#8217;ve used it for years with clients who want income and stability. Another one I use is iShares Select Dividend (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVY#NASDAQ">DVY</a>). That one focuses more on higher yields. It&#8217;s not always the right fit for everyone, but it works well if income is the top goal.&#8221;
SCHD currently offers a healthy 3.85% dividend; its year-to-date returns are 2.93% compared to 4.49% for its category.
<h3 class="wp-block-heading"> iShares Core High Dividend ETF</h3>
iShares Core High Dividend ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HDV#NYSE">HDV</a>) is another popular pick among money managers.
The fund holds 75 high-dividend-paying stocks and is energy-heavy, with Exxon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) and Chevron (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) comprising two of the top three fund holdings. Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) also joins the group. 
Big-cap brand names are the fund&#8217;s bread and butter, although no one stock tops 9.3% of its holdings (that would be Exxon). The fund is up 7.75% and has generally landed in the 10% annual return range since it launched in 2011. HDV also offers a robust 3.41% dividend yield with an ultra-low 0.8% expense ratio.
<h2 class="wp-block-heading">What To Look For With Dividend ETFs</h2>
Before you get rolling on dividend funds and kick some tires, have a game plan to leverage that matches you up with the right fund.
&#8220;You want an ETF that holds reliable stocks with a history of raising dividends annually, and that offers a true hedge against inflation,&#8221; said Ketti Rose, the CEO and founder of Wealthy Femme, a money management platform geared toward women investors. &#8220;Also, ensure the expense ratio is low – the less, the better, as there&#8217;s no need to sacrifice returns for fees.&#8221;
Additionally, seek out ETFs that maintained steady — or even increased — dividends through past recessions (e.g., in 2008 or 2020). &#8220;That&#8217;s a strength you can depend on,&#8221; Rose noted.
<h2 class="wp-block-heading">Predictable Trading In Unpredictable Times</h2>
In a market dominated by tariff tensions, geopolitical surprises and Fed uncertainty, Matt Maley's technical approach delivers clear entry/exit points for consistent income potential. Try it <a href="https://www.benzinga.com/premium/ideas/7-day-free-trial-matt-maley-inner-circle/?el=ResearchDaily&amp;he={{email}}&amp;adt_ei={{email}}&amp;utm_adType=SponsorAd&amp;utm_ad=RD0407&amp;utm_campaign=7daytrial">free for 7 days</a>. Gain Trading Confidence &amp; Income Potential. 
Photo: Shutterstock

Opinion

iShares Dow Jones Select Dividend Index Fund

SCHD

Sit Out Market Drama With These 3 Dividend Funds

Johnson &amp; Johnson&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) on Friday announced topline results from Phase&nbsp;3b&nbsp;APEX study of Tremfya (guselkumab) in patients with active psoriatic arthritis (PsA) who are biologic naïve and have had an inadequate <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">response to standard therapies</a>.
The study achieved its primary endpoint (ACR20a) of reducing signs and symptoms and its major secondary endpoint of reducing progression of structural damage as measured by radiographic progression at 24 weeks <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n44644676/tremfya-guselkumab-is-the-first-and-only-il-23-inhibitor-to-significantly-reduce-both-the-signs-an" rel="noreferrer noopener">compared to placebo</a>.
In the Phase&nbsp;3b&nbsp;APEX study, Tremfya-treated patients also exhibited significantly less progression of structural damage versus patients receiving a placebo at Week 24 as assessed by the PsA modified van der Heijde-Sharp (vdH-S) score, which includes joint space narrowing and erosion subscores.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44586129/us-judge-rejects-another-johnson-johnson-attempt-to-use-bankruptcy-for-talc-cancer-claims" rel="noreferrer noopener">US Judge Rejects Another Johnson &amp; Johnson Attempt To Use Bankruptcy For Talc Cancer Claims</a>
Data were consistent with the well-established safety profile of Tremfya&nbsp;with no new safety signals identified.
APEX is a Phase&nbsp;3b&nbsp;study with long-term extension data through three years that will further assess the sustained efficacy of Tremfya&nbsp;on inhibition of structural damage in patients with active PsA.
Results from the APEX study are being prepared for presentation at upcoming medical congresses.
<h2 class="wp-block-heading">Johnson &amp; Johnson Stock Prediction For 2025</h2>
Equity research analysts on and off Wall Street typically use earnings growth and fundamental research as a form of valuation and forecasting. But many in trading turn to technical analysis as a way to form predictive models for share price trajectory.
Some investors look to trends to help forecast where they believe a stock could trade at a certain point in the future. Looking at Johnson &amp; Johnson, an investor could make an assessment about a stock's long term prospects using a moving average and trend line. If they believe a stock will remain above the moving average, which many believe is a bullish signal, they can extrapolate that trend into the future using a trend line. For Johnson &amp; Johnson, the 200-day moving average sits at $156.5, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, which is above the current price of $155.82. For more on charts and trend lines, <a href="https://pro.benzinga.com/">see a description here.</a>
Traders believe that when a stock is above its moving average, it is a generally bullish signal, and when it crosses below, it is a more negative signal. Investors could use trend lines to make an educated guess about where a stock could trade at a later date if conditions remain stable.
Price Action: JNJ stock is down 3.51% at $154.21 at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/buybacks/25/04/44647720/matador-resources-sells-eagle-ford-assets-announces-potential-buybacks" target="_blank" rel="noreferrer noopener">Matador Resources Sells Eagle Ford Assets, Announces Potential Buybacks</a></li>
</ul>
Photo by Tada Images via Shutterstock

Johnson & Johnson's Tremfya Shows Efficacy In Late-Stage Psoriatic Arthritis Study

TREMFYA&#xAE; demonstrated clinically meaningful and statistically significant efficacy in patients with active psoriatic arthritis at risk for structural damage in Phase 3b study
Topline results demonstrate efficacy across multiple domains at Week 24, reinforcing TREMFYA&#xAE; as a first-line treatment option for patients with active psoriatic arthritis
SPRING HOUSE, Pa., April 4, 2025 /PRNewswire/ -- Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) today announced that the TREMFYA&#xAE; (guselkumab) Phase 3b APEX study achieved both its primary endpoint (ACR20a) of reducing signs and symptoms and its major secondary endpoint of reducing progression of structural damage as measured by radiographic progression at 24 weeks, in adults living with active psoriatic arthritis (PsA), compared to placebo.1

Johnson & Johnson Announces TREMFYA Is The First And Only IL-23 Inhibitor To Reduce Both The Signs And Symptoms And The Progression Of Structural Damage In Adults Living With Active Psoriatic Arthritis

President Donald Trump on Wednesday announced a slew of tougher-than-anticipated tariffs, but there are some <a href="https://www.whitehouse.gov/fact-sheets/2025/03/fact-sheet-president-donald-j-trump-addresses-the-threat-to-national-security-from-imports-of-timber-lumber-and-their-derivative-products/">notable exemptions</a> to the steep levies.&nbsp;
Here's a look at which products and sectors are excluded <a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44626421/trumps-reign-of-tariffs-unleashes-d-day-on-wall-street-analyst-warns-of-stagflation-risk">from the reciprocal tariffs:&nbsp;</a>
Semiconductors: Semiconductors were exempted from the sweeping new tariffs due to their critical role in many technologies. However, the sector was deep in the red in Thursday's trading with shares of Broadcom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) down 6.78% and ASML Holding N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>) down 3.69%.&nbsp;
Read Next: <a href="https://www.benzinga.com/news/global/25/04/44628368/trumps-tariffs-prompt-china-to-vow-countermeasures-experts-see-retaliation-likely">Trump&#8217;s Tariffs Prompt China To Vow &#8216;Countermeasures&#8217;: Experts See Retaliation Likely&nbsp;</a>
Pharmaceuticals: Trump excluded pharmaceuticals from the new tariffs, likely a relief for the industry that had been under pressure following the president's prior comments suggesting a 25% tariff on pharmaceutical imports.&nbsp;
"The United States can no longer produce enough antibiotics to treat our sick," Trump said Wednesday. "We have a tremendous problem, we have to go to foreign countries to treat our sick. If anything ever happened from a war standpoint, we wouldn't be able to do it."
Pharmaceutical stocks are defying Thursday's broad market drop with shares of AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) and Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) both in the green in mid-morning trading. 
Lumber: Lumber is another product excluded from Trump's tariff plan, for now. The administration said it is investigating how reliance on imported lumber impacts national security and economic stability. Exemptions have been granted to avoid immediate disruptions in supply chains critical to construction and defense in the meantime.&nbsp;
Gold, Copper: Certain metals and minerals including copper, gold and others not found in the U.S. were also exempted from the reciprocal tariff plan.&nbsp;
Gold dropped more than 3%, falling below $3,060 per ounce on Thursday after touching a new record high above $3,160. The SPDR Gold Trust ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>), tracking the price of gold, was down only slightly, bucking the broader market declines.&nbsp;
Energy: Oil, gas and refined products imports were exempted from the sweeping new reciprocal tariffs, the White House said on Wednesday.&nbsp;
Shares of the United States Oil Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USO#NYSE">USO</a>) fell 7.8% on Thursday, however, as the sweeping tariff plan could threaten global demand.&nbsp;
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/03/44537429/cathie-wood-doubles-down-on-2600-tesla-stock-price-prediction">Cathie Wood Doubles Down On $2,600 Tesla Stock Price Prediction</a></li>
</ul>
Photo: Shutterstock/Alones

Government

Specialty ETFs

Commodities

Politics

Global

Economics

Movers

Tech

ABBV

ASML

AVGO

Trump's Tariff Exemptions Include Semiconductors, Pharmaceuticals, Oil And More

RBC Capital analyst Shagun Singh reiterates Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) with a Outperform and maintains $181 price target.

Reiteration

RBC Capital Reiterates Outperform on Johnson & Johnson, Maintains $181 Price Target

For many investors, dividend-focused <a href="https://in.benzinga.com/25/03/44565770/30-year-old-with-65k-in-stocks-sparks-debate-focusing-mostly-on-etfs-but-now-betting-on-bonds-small-caps-and-international-plays">stocks</a> and funds provide a way to generate passive income, whether to supplement retirement, cover day-to-day <a href="https://in.benzinga.com/personal-finance/25/02/43768530/should-married-couples-split-expenses-dave-ramsey-says-no-youre-married-not-roommates">expenses</a>, or even finance small luxuries like annual vacations.
While some aim for significant <a href="https://in.benzinga.com/personal-finance/25/03/44518501/20-year-old-university-student-wants-help-with-buying-dividend-stocks-whats-the-best-way-to-start-reddit-weights-in">dividend</a> payouts to replace their salary, others are happy with modest but constant returns that offer a little extra financial freedom.
Don't Miss:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
<li>If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?</li>
</ul>
This is the case of a Reddit user who is exploring this approach. With $30,000 to invest, he's seeking long-term dividend stocks that can grow over the next 20 years until retirement. While he already holds dividend-paying stocks like Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) and Walt Disney&nbsp; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>), he wants to expand his portfolio for stability and future income, even if it's just enough to cover yearly vacations.
&#8220;I currently have some stocks that give out dividends (Apple, Disney) but I&#8217;m looking for others. Long-term stability, that my wife and I can use the dividends as another form of income say in 20 years. Even if it&#8217;s just enough to pay for a yearly vacation here or there. Any thoughts on good companies to choose from?&#8221; he asked.
Let&#8217;s break down the Redditors&#8217; advice received in the comment section.
Trending: BlackRock is calling 2025 the year of alternative assets. <a href="https://www.benzinga.com/money/masterworks">One firm from NYC has quietly built a group of 60,000+ investors who have all joined in on an alt asset class previously exclusive to billionaires like Bezos and Gates.</a>
<h2 class="wp-block-heading">Where to Invest $30,000 to Generate Enough Income to Cover Yearly Vacations? Reddit Answers</h2>
Put the Money in an ETF
Several commenters recommended Schwab U.S. Dividend Equity ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHD#NYSE">SCHD</a>) as a core holding because of its dividend yield, historical growth, and the low-risk, diversified exposure it offers investors.
&#8220;Go all in SCHD. Low risk, nice 3.5% starting yield and it will just keep growing,&#8221; a commenter said.
Reinforcing the idea that SCHD fits the poster&#8217;s long-term stability and dividend payout need, this Redditor also suggested he goes with SCHD: &#8220;Since you want some growth and decent payout, SCHD is a great option. 3.5% dividends and 11% growth over the last 10 years each year.&#8221;
&#8220;I would stick with S&amp;P 500 ETFs being young. Put it in a self-direct investment retirement account to avoid taxes,&#8221; a comment reads.
See Also: Have $200K saved?<a href="https://www.benzinga.com/money/have-200k-saved-heres-how-to-turn-it-into-lasting-wealth"> Here's how to turn it into lasting wealth</a>
Consider High-Yield Dividend Stocks and Trusts
Several commenters suggested higher-yield assets that would generate higher payouts for the investor in the long run.
&#8220;If you want higher yield stocks check: [Verizon Communications (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/vz#NYSE">VZ</a>)], [AT&amp;T (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/t#NYSE">T</a>)], [Realty Income Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/o#NYSE">O</a>)], [Altria Group (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mo#NYSE">MO</a>)], [British American Tobacco (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bti#NYSE">BTI</a>)],&#8221; a Redditor recommended.
A commenter mentioned United Parcel Service (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>) as a great pick since the company seems to start focusing on higher profit margin areas.
&#8220;UPS pays a solid dividend and the share price has been beaten down a lot on the news that they are reducing Amazon deliveries to focus on higher profit margin areas,&#8221; he said.
Suggesting a very detailed portfolio allocation, this Redditor mentioned several ETFs and individual stocks that he considers would help the poster reach his dividend and growth goals.
&#8220;[Vanguard S&amp;P 500 ETF (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/voo#NYSE">VOO</a>)] $5,000, 1.25% dividends. Do [dividend reinvestment plan] SCHD $5,000, 3.5% dividends. Do [dividend reinvestment plan], [JPMorgan Equity Premium Income ETF (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/jepi#NYSE">JEPI</a>)], [JPMorgan Nasdaq Equity Premium Income ETF (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jepq#NASDAQ">JEPQ</a>)​] ($5,000), 8% combined dividends. Do [dividend reinvestment plan] [Old Republic International Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ori#NYSE">ORI</a>)] $2,000, 3% dividends. Do [dividend reinvestment plan] [Waste Management (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/wm#NYSE">WM</a>)] and [Automatic Data Processing (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adp#NASDAQ">ADP</a>)] ($3,000), 2% average dividend. Do [dividend reinvestment plan] [Pfizer (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pfe#NYSE">PFE</a>)] and [Johnson &amp; Johnson (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/jnj#NYSE">JNJ</a>)] $2,000, 4.75% average dividend. Do [dividend reinvestment plan] [JPMorgan Chase &amp; Co. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/jpm#NYSE">JPM</a>)] and [UnitedHealth Group Incorporated (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/unh#NYSE">UNH</a>)] $2,000, 2% average dividends. Do [dividend reinvestment plan] AAPL and [Microsoft (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/msft#NASDAQ">MSFT</a>)] $2,000. [The Coca-Cola Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ko#NYSE">KO</a>)] and MO $2,000, 5% average dividends. Do [dividend reinvestment plan] JPM or [American Express (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/axp#NYSE">AXP</a>)] $2,000. JPM has good potential growth,&#8221; the suggestion says.
Read Next:
<ul>
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
</ul>

Personal Finance

AAPL

JEPI

JEPQ

MSFT

Man With $30K To Deploy Wants Dividends For Life – 'Even If It's Just Enough To Pay For A Yearly Vacation Here Or There,' Reddit Reacts

13 analysts have expressed a variety of opinions on Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $166.85, along with a high estimate of $181.00 and a low estimate of $152.00. Observing a downward trend, the current average is 1.94% lower than the prior average price target of $170.15. 
<img src="https://www.benzinga.com/files/images/story/2025/1743627702_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The analysis of recent analyst actions sheds light on the perception of Johnson &amp; Johnson by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$181.00</td>
<td>$181.00</td>
</tr>
<tr>
<td>Tim Anderson</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$171.00</td>
<td>$159.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$181.00</td>
<td>$181.00</td>
</tr>
<tr>
<td>Vamil Divan</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Neutral</td>
<td>$166.00</td>
<td>$162.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$166.00</td>
<td>$159.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$181.00</td>
<td>$181.00</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$163.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$155.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>David Risinger</td>
<td>Leerink Partners</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$169.00</td>
<td>$182.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$152.00</td>
<td>$166.00</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$165.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Tim Anderson</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$159.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Tim Anderson</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$160.00</td>
<td>$166.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Johnson &amp; Johnson. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Johnson &amp; Johnson compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Johnson &amp; Johnson's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Johnson &amp; Johnson's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/JNJ/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Johnson &amp; Johnson analyst ratings.</a>
<h2>Discovering Johnson &amp; Johnson: A Closer Look</h2>
Johnson &amp; Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
<h3>Johnson &amp; Johnson's Financial Performance</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Johnson &amp; Johnson's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 5.26%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Johnson &amp; Johnson's net margin excels beyond industry benchmarks, reaching 15.24%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Johnson &amp; Johnson's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.84% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.91%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.51, Johnson &amp; Johnson adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Significance of Analyst Ratings Explained</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 13 Analyst Ratings Have To Say About Johnson & Johnson

Shares of Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) are trading higher on Wednesday. <a href="https://www.benzinga.com/trading-ideas/movers/25/04/44594161/johnson-johnson-stock-is-tumbling-tuesday-what-going-on">Yesterday, they were down more than 7.5%</a>.  Analysts attribute the move lower to the company's announcement that its pending acquisition of Intra-Cellular Therapies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) will dilute its earnings.
But the sell-off may have ended, and there is a good chance Johnson &amp; Johnson rallies. This is why our team of trading experts has made it our Stock of the Day.
You can see on the chart below that the selloff ended when the shares reached the $153 level. This wasn't a coincidence. This price level was resistance in November. Price levels that had been resistance converting into support is a frequent occurrence in the financial markets.
It is due to investor and trader psychology.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="529" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02122026/one4-1024x529.png" alt="" class="wp-image-853722" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02122026/one4-1024x529.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02122026/one4-300x155.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02122026/one4-768x397.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02122026/one4-1536x793.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02122026/one4.png 1615w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Also: <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44609851/from-seashells-to-satoshi-why-cryptocurrency-is-the-next-natural-evolution-of-money">From Seashells To Satoshi: Why Cryptocurrency Is The Next Natural Evolution Of Money</a>
Some people who sold Johnson &amp; Johnson around $153.00 thought they made a good decision to sell when the price trended lower after. But when the resistance was broken in February, many of these unhappy sellers second-guessed themselves.
Some believed their decision to sell was a mistake and vowed to return their shares. But they would only do so if they could eventually get them at the same price they were sold for.
As a result, when the shares fell to around $153 yesterday, these formerly happy sellers entered the market as buyers. There were so many of them that it put a floor beneath the price. It created support at the same price that had been resistance.
Johnson &amp; Johnson may reverse and move higher.
Some of the buyers who formed this support may become concerned that they will be outbid. They may think there are others who would be willing to pay higher prices than they will, and they know that these are the sellers who will go to them.
Because of this, they increase their bid prices to get ahead of other buyers. Other concerned buyers could see this, and raise their bid prices to get ahead of others as well.
This dynamic could result in a bidding war that forces Johnson &amp; Johnson into an uptrend.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44607188/arthur-hayes-predicts-bitcoin-to-hit-250000-by-end-of-year">Arthur Hayes Predicts Bitcoin To Hit $250,000 By End Of Year</a></li>
</ul>
Image: Shutterstock

Technicals

ITCI

Stock Of The Day: Will Johnson & Johnson Rally? The Sell-Off May Have Ended

Guggenheim analyst Vamil Divan reiterates Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) from Neutral to Neutral.

Guggenheim Reiterates Neutral on Johnson & Johnsonto Neutral

-ReutersAdvances Company's industry-leading portfolio in mental health with addition of CAPLYTA&#xAE; (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an adjunctive therapy and monotherapy; also approved for the treatment of schizophrenia in adults
sNDA submitted to U.S. FDA for CAPLYTA&#xAE; as adjunctive treatment for major depressive disorder; if approved, has potential to become a new standard of care for most common depressive disorders
Addition of CAPLYTA&#xAE; strengthens J&amp;J's robust lineup of therapies with $5 billion+ potential in peak year salesi, further solidifying sales growth above analyst expectations now through the remainder of the decade
Acquisition also includes promising clinical-stage pipeline with best-in-class potential in generalized anxiety disorder and Alzheimer's disease-related psychosis and agitation
Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) today announced it has completed its acquisition of Intra-Cellular Therapies, Inc. Intra-Cellular Therapies is now part of Johnson &amp; Johnson and will operate as a business unit within Johnson &amp; Johnson Innovative Medicine.
"At Johnson &amp; Johnson, we are committed to transforming care for the millions of people worldwide living with neuropsychiatric and neurodegenerative disorders," said Joaquin Duato, Chairman and Chief Executive Officer, Johnson &amp; Johnson. "We are excited to officially welcome the talented Intra-Cellular Therapies team to the Company, and we look forward to working together as we realize our ambition of becoming the number one neuroscience company worldwide."
With this acquisition, Johnson &amp; Johnson adds CAPLYTA&#xAE; (lumateperone) to its robust portfolio of differentiated medicines. CAPLYTA&#xAE; is a once-daily oral therapy approved to treat adults with schizophrenia, as well as the first and only U.S. Food and Drug Administration (FDA)-approved treatment for depressive episodes associated with bipolar I or II disorder (bipolar depression), as a monotherapy and adjunctive therapy with lithium or valproate. In February 2025, Intra-Cellular Therapies announced that the U.S. FDA accepted its supplemental new drug application for CAPLYTA&#xAE; as an adjunctive treatment for adults with major depressive disorder (MDD). The acquisition also includes ITI-1284, a promising Phase 2 compound being studied in generalized anxiety disorder (GAD) and Alzheimer's disease-related psychosis and agitation, as well as a clinical-stage pipeline that further complements Johnson &amp; Johnson's current areas of focus.
"We are focused on investing in what we believe is the future of innovation across our targeted therapeutic areas, including neuroscience," said Jennifer Taubert, Executive Vice President, Worldwide Chairman, Innovative Medicine, Johnson &amp; Johnson. "We are pleased to finalize this acquisition, which serves as a strategic near- and long-term growth catalyst for Johnson &amp; Johnson, and we look forward to working together to continue transforming treatment and patient care for some of today's most debilitating neuropsychiatric and neurodegenerative disorders."

Johnson & Johnson Closes Intra-Cellular Therapies Acquisition; Expects Deal To Dilute Adj EPS By ~$0.25 in 2025

U.S. stocks closed higher on Tuesday, with the Nasdaq Composite climbing 0.9% to 17,449.89. The S&amp;P 500 added nearly 0.4%, finishing at 5,633.07, while the Dow edged down 0.03% to 41,989.96. Market optimism was <a href="https://in.benzinga.com/news/earnings/25/04/44591098/nasdaq-surges-1-us-construction-spending-rises-in-february">supported by a 0.7% rise in U.S. construction spending</a> for February. Even so, uncertainty persists as President Donald Trump&#8217;s &#8220;Liberation Day&#8221; moves put <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44598088/trumps-liberation-day-creates-major-uncertainty-for-big-tech-analyst-dan-ives-says">pressure on tech stocks</a>.
These are the top stocks that gained the attention of retail traders and investors throughout the day:
Newsmax Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NMAX#NYSE">NMAX</a>)
Newsmax shares soared by a whopping 179.01%, closing at $233. The stock&#8217;s intraday high was $265, with a low of $114.22. This comes after the conservative cable news network went public at $10 per share and quickly surged over 500% on its first day of trading. The stock&#8217;s 52-week high and low stand at $265 and $14, respectively. The stock slipped more than 18% in after-hours trading.
Newsmax&#8217;s public debut highlights its rapid growth as the fourth-largest cable news channel, with CEO Christopher Ruddy positioning it as a <a href="https://in.benzinga.com/trading-ideas/movers/25/04/44593007/newsmax-stock-soars-more-than-100-as-ipo-momentum-continues-whats-going-on">high-growth network</a> amid rising conservative viewership and investor interest.
Waton Financial Limited&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTF#NASDAQ">WTF</a>)
Waton Financial shares skyrocketed by 396.25%, closing at $19.85. The stock&#8217;s intraday high and low were both at $19.85, with a 52-week high and low of $19.85 and $4.05, respectively. This surge followed the company&#8217;s announcement of the pricing of its initial public offering of an aggregate of 4,375,000 ordinary shares at a public offering price of $4.00 per share. 
See Also: <a href="https://benzinga.com/analyst-ratings/price-target/25/04/44587443/blackberry-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call" target="_blank" rel="noreferrer noopener">BlackBerry Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a>
Johnson &amp; Johnson Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)
Johnson &amp; Johnson shares tumbled by 7.59%, closing at $153.25. The stock&#8217;s intraday high was $161.81, with a low of $153.13. This drop came after a U.S. bankruptcy court <a href="https://www.benzinga.com/trading-ideas/movers/25/04/44594161/johnson-johnson-stock-is-tumbling-tuesday-what-going-on">rejected</a> subsidiary Red River Talc&#8217;s request to approve its prepackaged bankruptcy plan. The stock&#8217;s 52-week high was $169.99 and low at $140.68. 
Hims &amp; Hers Health Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>)
Hims &amp; Hers Health shares spiked by 5.08%, closing at $31.05. The stock&#8217;s intraday high was $33.70, with a low of $28.76. The company announced that it will offer Eli Lilly And Co's Zepbound <a href="https://in.benzinga.com/25/04/44593851/hims-hers-health-stock-jumped-tuesday-afternoon-what-happened">through its Telehealth platform</a>, leading to a surge in its stock price. The stock&#8217;s 52-week high and low are $72.98 and $11.20, respectively. The shares slipped over 3% in the after-hours trading.
Tesla Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)
Tesla shares rose by 3.59%, closing at $268.46. The stock&#8217;s intraday high was $277.45, with a low of $259.25. Deepwater Asset Management&#8217;s Gene Munster warned investors of disappointing Tesla delivery numbers for the first quarter, predicting that the coming months could be even more challenging. The stock&#8217;s 52-week high was seen at $488.54 and low at $138.80. 
Benzinga Edge Stock Rankings show Tesla Momentum in the 90th percentile and Growth in the 67th percentile. Wondering how Rivian compares? <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">Find out here</a>.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" width="694" height="106" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/01222507/Screenshot-2025-04-02-at-11.24.16.png" alt="" class="wp-image-852317" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/01222507/Screenshot-2025-04-02-at-11.24.16.png 694w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/01222507/Screenshot-2025-04-02-at-11.24.16-300x46.png 300w" sizes="(max-width: 694px) 100vw, 694px" /></a></figure>
Photo: Shutterstock
Prepare for the day&#8217;s trading&nbsp;<a href="https://editorial.benzinga.com/wp-admin/Premarket%20Movers%20&amp;%20News">with top premarket movers and news</a>&nbsp;by Benzinga.
Read Next: 
<ul>
<li><a href="https://benzinga.com/markets/equities/25/04/44578839/trumps-25-tariff-on-imported-vehicles-could-shatter-detroits-auto-economy-warns-business-leaders">Trump&#8217;s 25% Tariff On Imported Vehicles Could Shatter Detroit&#8217;s Auto Economy, Warns Business Leaders: &#8216;It Will Hurt Hardworking Americans&#8217;</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

Equities

Hims & Hers Health, Inc. Class A Common Stock

HIMS

NMAX

TSLA

Newsmax, Waton Financial, Johnson & Johnson, Hims & Hers Health, Tesla: Why These 5 Stocks Are On Investors' Radars Today

Johnson & Johnson Announces Expected Closing Date For Intra-Cellular Acquisition; To Complete Intra-Cellular Acquisition Around April 2, 2025

Management

Press Releases

Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan

New nipocalimab data and real-world research at AAN 2025 highlight positive Phase 3 results and commitment to people living with generalized myasthenia gravis (gMG)

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) outperforms osimertinib with a significant and unprecedented overall survival benefit in patients with EGFR-mutated non-small cell lung cancer

Johnson & Johnson to Return to Tort System to Defeat Meritless Talc Claims

Federal Judge Rejects Johnson & Johnson Bankruptcy Strategy, Paving Way for Talc Victims to Seek Justice in Trial Courts

Johnson & Johnson Announces Expected Closing Date for Intra-Cellular Acquisition

Johnson & Johnson Closes Landmark Intra-Cellular Therapies, Inc. Acquisition to Solidify Neuroscience Leadership

TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to significantly reduce both the signs and symptoms and the progression of structural damage in adults living with active psoriatic arthritis

Johnson & Johnson to Participate in the BofA Securities 2025 Healthcare Conference

Johnson & Johnson highlights new data that showcase the strength of nipocalimab, demonstrating long-term sustained disease control in adults living with generalized myasthenia gravis (gMG)

TVGN

TVGNW

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Indus

Verona Pharma plc - American Depositary Shares

Verona Pharma

Viatris

Zoetis

RBC Capital

B of A Securities

Barclays

Morgan Stanley

Stifel

Screenshot 2024-09-30 at 9.13.36 PM

TNXP

VRTX

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

Screenshot 2024-04-30 at 5.36.02 PM

Cardio Diagnostics Holdings Inc. - Common stock

Comments

Johnson & Johnson

Interés en corto

Johnson & Johnson (NYSE:JNJ) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL